DMAC

DiaMedica Therapeutics Inc

Add to Watchlist

Advanced Chart

5.930

-0.07(-1.167%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.050

Open

6.000

VWAP

5.89

Vol

128.99K

Mkt Cap

306.52M

Low

5.8001

Amount

759.43K

EV/EBITDA(TTM)

Total Shares

37.96M

280.12M

EV/OCF(TTM)

P/S(TTM)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.200

+11.11%

-0.167

-7.41%

-0.160

+6.67%

Estimates Revision

The market is revising No Change the revenue expectations for DiaMedica Therapeutics Inc. (DMAC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 43.58%.

EPS Estimates for FY2025

Revise Downward

-2.61%

In Past 3 Month

Stock Price

Go Up

+43.58%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is 12.33 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.930

Low

11.00

Averages

12.33

High

14.00

Current: 5.930

Low

11.00

Averages

12.33

High

14.00

H.C. Wainwright

NULL -> Buy

upgrade

$10 -> $12

2025-07-18

Reason

H.C. Wainwright

Price Target

$10 -> $12

2025-07-18

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on DiaMedica Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is "tangible evidence" for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.

Lake Street

Buy

maintain

$11 -> $14

2025-07-18

Reason

Lake Street

Price Target

$11 -> $14

2025-07-18

maintain

Buy

Reason

Lake Street raised the firm's price target on DiaMedica Therapeutics to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees "materially" improving the prospects for DM199 in this indication.

Craig-Hallum

Chase Knickerbocker

Buy

maintain

$8 -> $11

2025-07-18

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$8 -> $11

2025-07-18

maintain

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on DiaMedica Therapeutics to $11 from $8 and keeps a Buy rating on the shares following interim results from Part 1a of its Phase 2 trial evaluating DM199 for preeclampsia. The data showed clinically meaningful reductions in both systolic and diastolic blood pressure, with the highest dose group experiencing acute drops of 35 mmHg and 15 mmHg respectively at 5 minutes. While the sample size remains small, the 24-hour average reductions of 20 mmHg systolic and 10 mmHg diastolic are encouraging and the firm says potentially clinically meaningful. These results support continued development into Part 1b and beyond, Craig-Hallum adds. Importantly, evidence suggests DM199 did not cross the placental barrier.

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Maintains

$7 → $10

2025-03-19

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$7 → $10

2025-03-19

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

2024-11-15

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

2024-10-10

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2024-10-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC.O) is -7.94, compared to its 5-year average forward P/E of -5.03. For a more detailed relative valuation and DCF analysis to assess DiaMedica Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.03

Current PE

-7.94

Overvalued PE

-2.49

Undervalued PE

-7.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.83

Current EV/EBITDA

-6.89

Overvalued EV/EBITDA

-0.27

Undervalued EV/EBITDA

-5.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00